Table 4 Correlation between different adherence levels and VL >400 copies/ml at week 24: a) among all women and b) among women exposed vs. not exposed to sdNVP separately

100% (n = 28)

1

Ever <100% (n = 119)

2.5 (0.3-111.4); 0.69*

>95% (n = 92)

1

Ever <95% (n = 55)

2.1 (0.5-9.3); 0.33*

>90% (n = 105)

1

Ever <90% (n = 42)

2.2 (0.5-9.3); 0.30*

>80% (n = 122)

1

Ever <80% (n = 25)

4.8 (1.0-20.8); 0.02*

>70% (n = 137)

1

Ever <70% (n = 10)

6.9 (1.0-37.7); 0.03*

b)

Percent adherence during any of the visits 2- 24 weeks

≤ 400 copies/ml

> 400 copies/ml

Univariable odds ratio

(CI 95%); p value

100% (n = 18)

18 (21%)

0

1

Ever <100% (n = 72)

67 (79%)

5 (100%)

NA: 0.58*

>95% (n = 62)

61 (72%)

1 (20%)

1

Ever <95% (n = 28)

24 (28%)

4 (80%)

10.2 (0.9-508.5); 0.03*

>90% (n = 69)

68 (80%)

1 (20%)

1

Ever <90% (n = 21)

17 (20%)

4 (80%)

16 (1.4-798.9); 0.01*

>80% (n = 75)

74 (87%)

1 (20%)

1

Ever <80% (n = 15)

11 (13%)

4 (80%)

26.9 (2.2-1341.7); <0.01*

>70% (n = 83)

80 (94%)

3 (60%)

1

Ever <70% (n = 7)

5 (6%)

2 (40%)

10.7 (0.7-112.3); 0.01*

≤ 400 copies/ml

> 400 copies/ml

Univariable odds ratio

(CI 95%); p value

100% (n = 10)

9 (18%)

1 (17%)

1

Ever <100% (n = 47)

42 (82%)

5 (83%)

1.1 (0.1-56.2); 1.00*

>95% (n = 30)

26 (51%)

4 (67%)

1

Ever <95% (n = 27)

25 (49%)

2 (33%)

0.5 (0-4.1); 0.67*

>90% (n = 36)

31 (61%)

5 (83%)

1

Ever <90% (n = 21)

20 (39%)

1 (17%)

0.3 (0-3.1); 0.40*

>80% (n = 47)

42 (82%)

5 (83%)

1

Ever <80% (n = 10)

9 (18%)

1 (17%)

0.9 (0-10.0); 1.00*

>70% (n = 54)

49 (96%)

5 (83%)

1

Ever <70% (n = 3)

2 (4%)

1 (17%)

4.9 (0.1-106.0); 0.29*